Ovelle plans to introduce its revolutionary in vitro gametogenesis (IVG) technology by initially focusing on patients for whom traditional IVF is not an option, such as cancer survivors. This builds a user base and proves the technology's safety and efficacy before targeting the broader, more cautious IVF market.
Ovelle's founding was catalyzed by Travis Potter discovering Merrick Smela's published papers. Merrick's public presence and clear communication of his work made him discoverable. This demonstrates that for scientific entrepreneurs, sharing expertise openly is a powerful tool for inbound recruiting and fundraising.
In a tough funding climate, Ovelle successfully raised capital by focusing on investors who personally understood the problem of infertility. This strategy sidesteps the need to educate uninterested parties and instead builds a base of long-term partners who share the company's vision, proving more effective than a broad approach.
Faced with limited resources, Ovelle's team identifies the absolute minimal steps required to create a viable egg. They focus only on tasks directly related to these key milestones (e.g., DNA methylation, meiosis, egg growth), shelving all other interesting but non-essential research directions.
Merrick Smela found the switch from academia to his startup, Ovelle, to be a small one. During his PhD, he operated with a clear, product-focused goal: "I want to make an egg." This contrasts the stereotype of purely exploratory academic research, showing that a mission-driven approach is excellent training for entrepreneurship.
Instead of mimicking slow, natural signaling (a process taking over a decade), Ovelle's approach directly activates gene regulatory factors that initiate meiosis. This method is significantly faster—starting the process in just 12 days—and offers more precise control over cell generation.
Former Goldman Sachs director Travis Potter co-founded Ovelle after personal struggles with IVF revealed its lack of innovation since 1978. Shocked by the minuscule global research funding, he was inspired to apply his business acumen to accelerate progress in a field he saw as critically under-supported.
Because in vitro gametogenesis is so new, there's no pre-existing talent pool. Ovelle's hiring strategy prioritizes finding intelligent scientists who can learn quickly. Scientific co-founder Merrick Smela emphasizes that his ability to train these new hires is a critical contribution to the company's success.
Ovelle's co-founders exemplify a common success pattern in biotech: one partner with profound scientific knowledge (Merrick) and another with extensive business experience (Travis). This combination covers critical aspects from research to capital raising and team building, as it's rare to find both skill sets in one person.